MedTrace Logo

A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.

NCT00736593 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2009-04-27

No results posted yet for this study

Summary

Nexagon™ is a novel compound that promotes wound healing by temporarily disrupting cellular communication at the wound site, thereby promoting accelerated healing, reducing inflammation and pain. This randomized double-blind study will assess the safety, tolerability and clinical effect of Nexagon™ when applied to skin wounds created by punch biopsy in healthy volunteers. 43 healthy, fair-skinned males and females between ages 18-40 will be enrolled. Subjects will be reviewed again at 3 months and 9 months for follow-up safety assessments and wound appearance evaluation.

Conditions

  • Wound Healing

Interventions

DRUG

Nexagon™ or Nexagon™ vehicle

Sponsors & Collaborators

  • OcuNexus Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Rod Ellis-Pegler · Auckland Clinical Studies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-01-31
Completion
2009-04-30

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736593 on ClinicalTrials.gov